PT-141 (Bremelanotide)

PT-141, also known as bremelanotide, is a synthetic cyclic heptapeptide classified as a melanocortin-receptor agonist. It is structurally derived from Melanotan II and has been characterized in laboratory settings for its interactions with melanocortin receptors, notably MC4R. Research interest centers on its centrally mediated profile rather than peripheral vascular activity. The compound is supplied strictly for in-vitro and laboratory research use only.

PT-141 is studied for agonist activity at melanocortin receptors, with emphasis on the MC4R subtype expressed in the central nervous system. Experimental work examines how this receptor engagement modulates neural circuits linked to sexual-arousal and motivation pathways. Investigations distinguish these central signaling events from nitric-oxide or vascular smooth-muscle mechanisms studied with other agents. Downstream pathways under scrutiny include hypothalamic and limbic neurotransmitter systems in model preparations.

Laboratory research on PT-141 focuses on centrally mediated MC4R signaling and its influence on sexual-response pathways in animal models. Studies compare its receptor selectivity and behavioral readouts with those of related peptides such as Melanotan II. Additional work explores structure-activity relationships of the cyclic peptide scaffold in binding and functional assays. All investigations remain confined to controlled in-vitro systems and preclinical model organisms.

Preclinical literature documents that PT-141 engages MC4R and related melanocortin receptors, producing measurable changes in central pathways distinct from peripheral vascular routes. In rodent models, experimental administration has been associated with alterations in sexual-motivation and arousal-related behavioral metrics. The cyclic structure is noted to contribute to receptor-binding characteristics observed in vitro. Findings consistently highlight a mechanism centered on brain circuitry rather than blood-flow modulation.

PT-141 is intended solely for laboratory research and must be handled under standard peptide-handling protocols. Stability is typically maintained by refrigerated or frozen storage, with reconstitution performed in suitable solvents for assay use. Researchers designing receptor-binding or cell-signaling experiments should account for its cyclic peptide properties. Work is restricted to in-vitro and non-clinical model systems; the material is not for human or animal consumption.